Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined medicine for inhibiting formation of ubiquitous drug-resistant acinetobacter baumannii biofilm

A biofilm, bacteria-inhibiting technology, applied in antibacterial drugs, pharmaceutical formulations, organic active ingredients, etc., can solve the problem of undocumented inhibition, and achieve the effects of reducing virulence, improving inhibition and broad application prospects.

Inactive Publication Date: 2021-04-06
CHENGDU MEDICAL COLLEGE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this document does not record how to improve the inhibitory effect of drugs on the biofilm formation ability of XDRAB and reverse the drug resistance of XDRAB

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined medicine for inhibiting formation of ubiquitous drug-resistant acinetobacter baumannii biofilm
  • Combined medicine for inhibiting formation of ubiquitous drug-resistant acinetobacter baumannii biofilm
  • Combined medicine for inhibiting formation of ubiquitous drug-resistant acinetobacter baumannii biofilm

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1: Preparation of combined medicine

[0029] Combination medicines consist of the following two components:

[0030] Component 1: 128 μg / ml baicalin;

[0031] Component 2: 0.0625 μg / ml tigecycline.

Embodiment 2

[0032] Embodiment 2: preparation combined medicine

[0033] Combination medicines consist of the following two components:

[0034] Component 1: 128 μg / ml baicalin;

[0035] Component 2: 0.0317 μg / ml tigecycline.

Embodiment 3

[0036] Embodiment 3: preparation combined medicine

[0037] Combination medicines consist of the following two components:

[0038] Component 1: 128 μg / ml baicalin;

[0039] Component 2: 0.0158 μg / ml tigecycline.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a combined medicine for inhibiting formation of a ubiquitous drug-resistant acinetobacter baumannii biofilm. The combined medicine contains baicalin and tigecycline which are prepared from the same or different specification units and used for simultaneous or separate administration, and a pharmaceutically acceptable carrier. Experimental results show that compared with the single use of baicalin or tigecycline, the combined use of baicalin and tigecycline significantly improves the effect of the drug in inhibiting the formation of the XDRAB biofilm. The combined medicine provided by the invention has a remarkably improved effect of inhibiting the formation of an XDRAB biofilm, can reverse the drug resistance of XDRAB and reduce the toxicity of XDRAB, and has a wide application prospect in the preparation of anti-ubiquitous drug-resistant Acinetobacter baumannii medicines and medicines for preventing and treating diseases caused by ubiquitous drug-resistant Acinetobacter baumannii infection.

Description

technical field [0001] The invention belongs to the technical field of microbial medicine, and in particular relates to a combined medicine for inhibiting the biofilm formation of pan-drug-resistant Acinetobacter baumannii. Background technique [0002] Acinetobacter baumannii (Acinetobacter baumannii) is a non-fermentative aerobic Gram-negative opportunistic pathogen; due to the widespread use of antibacterial drugs and the strong ability of Acinetobacter baumannii to acquire drug resistance, it is , Acinetobacter baumannii has developed from drug-resistant bacteria to multi-drug-resistant bacteria, and then to pan-drug-resistant bacteria. Pan-drug-resistant Acinetobacter baumannii (XDRAB) has become an important cause of hospital outbreaks and refractory infections. one of the pathogenic bacteria. [0003] At present, for the treatment of diseases caused by XDRAB infection, the development and marketing of new drugs is slow, and conventional treatment drugs are facing sev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K31/65A61P31/04
CPCA61K31/65A61K31/7048A61P31/04A61K2300/00
Inventor 凌保东彭勤孟千琳
Owner CHENGDU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com